When Partnership Drives Progress: Reflections on the Vivasure Journey

The recent acquisition of Vivasure Medical by Haemonetics follows over a decade of collaboration between Vivasure and Orchestra BioMed. Over that time, Orchestra worked alongside the Vivasure team through early-stage fundraising, clinical development and next-generation advancement of the PerQseal® technology, including during the formation and evolution of Vivasure’s strategic relationship with Haemonetics.

2025 Reflections from OBIO CEO

Dear Fellow Shareholders,

As 2025 comes to a close, I want to take the opportunity to reflect on a year of important achievements that puts Orchestra BioMed in a very strong position for the year to come. This year saw our Company make substantive clinical, strategic, and financial progress: we advanced execution of both of our pivotal trial-stage programs, we strengthened and clarified our strategic partnerships, and we secured nearly $150 million in capital and capital commitments on favorable terms. 

Shareholder Call Series: Part 3 — Key Themes from the Analyst Q&A

Dear Shareholders,

To complement our two-part summary of Orchestra BioMed’s recent shareholder update call, we are highlighting the Q&A session that followed the prepared remarks. Given strong shareholder interest in the types of questions asked - and the additional clarity provided by management during the discussion - we believe a concise summary of the major themes will be helpful.

Shareholder Call Series: Part 1 — Building a Strong Capital Base and Strategic Alignment for Long-Term Growth

Dear Shareholders,

This blog is the first of a two-part summary from Chairman and CEO David Hochman’s recent shareholder update call, which offered a detailed perspective on Orchestra BioMed’s progress through what has been a highly productive and strategically defining year.

While the Company’s third-quarter financial results reflect disciplined execution, the call focused not on quarterly numbers, but on how Orchestra BioMed’s financing, partnerships, and pivotal-stage programs are shaping long-term value creation.

In this first part, we summarize the discussion of recent financing success and strategic alignment — how Orchestra BioMed has strengthened its capital foundation and optimized partnerships to advance its flagship programs, AVIM Therapy and Virtue SAB, from a position of operational and financial strength.

Unlocking the Value of Virtue SAB with the Achievement of Two Major Milestones - Why Investors Should Take Notice

Dear Shareholders,

OBIO | Strategic Recaps: The Power of Partnership and Future of AVIM Therapy